Prostate-specific membrane antigen is produced in tumor-associated neovasculature

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2674-2681

  Chang, Sam S ^a   O'Keefe, Denise S ^b   Bacich, Dean J ^b   Reuter, Victor E ^a,b   Heston, Warren D W ^a,b   Gaudin, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b George M O'Brien Urology Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MEMBRANE ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IN SITU HYBRIDIZATION; MALE; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0032740888     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res., 7: 927-936, 1987.
2. Israeli, R. S., Powell, C. T., Corr, J. G., Fair, W. R., and Heston, W. D. Expression of the prostate-specific membrane antigen. Cancer Res., 54: 1807-1811, 1994.
3. Lopes, A. D., Davis, W. L., Rosenstraus, M. J., Uveges, A. J., and Gilman, S. C. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from anti-prostate monoclonal antibody 7E11-C5. Cancer Res., 50: 6423-6429, 1990.
4. Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. W., and Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res., 3: 81-85, 1997.
5. Sokoloff, R. L., Norton, K. C., Gasior, C. L., Marker, K. M., and Grauer, L. S. Quantification of prostate-specific membrane antigen (PSMA) in human tissues and subcellular fractions. Proc. Am. Assoc. Cancer Res., 39: 265, 1998.
6. Wright, G. L., Haley, C., Beckett, M. L., and Schelhammer, P. F. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol. Oncol., 1: 18-28, 1995.
7. Wright, G. L., Jr., Grob, B. M., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., and Moriarty, R. Up-regulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 48: 326-334, 1996.
8. Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., and Murphy, G. P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer (Phila.), 82: 2256-2261, 1998.
9. Kawakami, M., and Nakayama, J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res., 57: 2321-2324, 1997.
10. O'Keefe, D. S., Su, S. L., Bacich, D. J., Horiguchi, Y., Luo, Y., Powell, C. T., Zandvliet, D., Russell, P. J., Molloy, P. L., Nowak, N. J., Shows, T. B., Mullins, C., Vonder Haar, R. A., Fair, W. R., and Heston, W. D. W. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta, 1443: 113-127, 1998.
11. Pinto, J. T., Suffoletto, B. P., Berzin, T. M., Qiao, C. H., Lin, S., Tong, W. P., May, F., Mukherjee, B., and Heston, W. D. W. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res., 2: 1445-1451, 1996.
12. Luthi-Carter, R., Barczak, A. K., Speno, H., and Coyle, J. T. Molecular characterization of human brain N-acetylated α-linked acidic dipeptidase (NAALADase). J. Pharmacol. Exp. Ther., 286: 1020-1025, 1998.
13. Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V., Knudsen, B., and Bander, N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res., 57: 3629-3634, 1997.
14. Grauer, L. S., Lawler, K. D., Marignac, J. L., Kumar, A., Goel, A. S., and Wolfert, R. L. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM protein in the LNCaP prostatic carcinoma cell line. Cancer Res., 58: 4787-4789, 1998.
15. Murphy, G. P., Greene, T. G., Tino, W. T., Boynton, A. L., and Holmes, E. H. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J. Urol., 160: 2396-2401, 1998.
16. Chang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., and Gaudin, P. B. Five different anti-PSMA antibodies confirm prostate-specific membrane antigen (PSMA) expression in tumor-associated neovasculature. Cancer Res., 59: 3192-3198, 1999.
17. Israeli, R. S., Powell, C. T., Fair, W. R., and Heston, W. D. W. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res., 53: 227-230, 1993.
18. Troyer, J. K., Feng, Q., Beckett, M. L., and Wright, G. L. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol. Oncol., 1: 29-37, 1995.
19. Troyer, J. K., Beckett, M. L., and Wright, G. L., Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate, 30: 232-242, 1997.
20. Israeli, R. S., Miller, W. H., Jr., Su, S. L., Powell, C. T., Fair, W. R., Samadi, D. S., Huryk, R. F., DeBlasio, A., Edwards, E. T., Wise, G. J., and Heston, W. D. W. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res., 54: 6306-6310, 1994.
21. Israeli, R. S., Miller, W. H., Jr., Su, S. L., Samadi, D. S., Powell, C. T., Heston, W. D., Wise, G. J., and Fair, W. R. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J. Urol., 153: 573-577, 1995.
22. Lucotte, G., Mercier, G., and Burckel, A. The use of nested RT-PCR of prostate-specific membrane antigen in blood cells: implications for the detection of haematogenous neoplastic cells in patients with prostate adenocarcinoma. Mol. Cell Probes, 12: 421-425, 1998.
23. Murphy, G. P., Maguire, R. T., Rogers, B., Partin, A. W., Nelp, W. B., Troychak, M. J., Ragde, H., Kenny, G. M., Barren, R. J., III, Bowes, V. A., Gregorakis, A. K., Holmes, E. H., and Boynton, A. L. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate, 33: 281-285, 1997.
24. Murphy, G. P., Kenny, G. M., Ragde, H., Wolfert, R. L., Boynton, A. L., Holmes, E. H., Misrock, S. L., Bartsch, G., Klocker, H., Pointner, J., Reissigl, A., McLeod, D. G., Douglas, T., Morgan, T., and Gilbaugh, J., Jr. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology, 51: 89-97, 1998.
25. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat. Med., 1: 27-31, 1995.
26. Folkman, J., and Cotran, R. Relation of vascular proliferation to tumor growth. Int. Rev. Exp. Pathol., 16: 207-248, 1976.
27. Wang, G., Dong, Z., Xu, G., Yang, Z., Shou, C., Wang, N., and Liu, T. The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J. Cancer Res. Clin. Oncol., 124: 615-620, 1998.
28. Holmgren, L., O'Reilly, M. S., and Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1: 149-153, 1995.
29. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M. L. W., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of mestastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
30. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
31. Saleh, M., Stacker, S. A., and Wilks, A. F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res., 56: 393-401, 1996.
32. Arora, N., Masood, R., Zheng, T., Cai, J., Smith, D. L., and Gill, P. S. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res., 59: 183-188, 1999.
33. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
34. Brown, L. F., Guidi, A. J., Tognazzi, K., and Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor and vascular stroma formation in neoplasia. Insights from in situ hybridization studies. J. Histochem. Cytochem., 46: 569-575, 1998.
35. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., and Fusenig, N. E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med., 3: 1222-1227, 1997.
36. 3: a new prognostic indicator in breast cancer. Clin. Cancer Res., 4: 2625-2634, 1998.
37. Heston, W. D. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology, 49: 104-112, 1997.